Flagship Ventures Opportunities Fund I General Partner LLC Net Worth

Flagship Ventures Opportunities Fund I General Partner LLC's Net Worth

Estimate Recalculated Sep 18, 2024 08:02PM EST

Who is Flagship Ventures Opportunities Fund I General Partner LLC

Flagship Ventures Opportunities Fund I General Partner LLC does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Kaleido Biosciences, Inc., Foghorn Therapeutics Inc., Evelo Biosciences, Inc., Rubius Therapeutics, Inc., and Axcella Health Inc..

SEC CIK

Flagship Ventures Opportunities Fund I General Partner LLC's CIK is 0001725004

Past Insider Trading and Trends

No data available

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Kaleido Biosciences, Inc.

Investor

Updated Feb 10, 2021

View Quote Details


Form 4	4.14%	215.00K	$11.50	$2.47M	Feb 10, 2021	19.58M	Purchase	—	Feb 08
Form 4	62.67%	2.00M	$7.50	$15.00M	Jun 08, 2020	19.36M	Purchase	—	Jun 04
Form 4	-21.29%	-10.14M	$15.00	$14.00M	Mar 06, 2019	39.98M	Buy-Options	—	Mar 04
Form 3	—	—	—	—	Feb 27, 2019	2.50M	—	—	—

Showing 4 results

Foghorn Therapeutics Inc.

Investor

Updated Oct 29, 2020

View Quote Details


Form 4	-45.30%	-10.50M	$16.00	—	Oct 29, 2020	12.67M	Buy-Options	—	Oct 27
Form 3	—	—	—	—	Oct 22, 2020	—	—	—	—

Showing 2 results

Axcella Health Inc.

Investor

Updated Oct 17, 2022

View Quote Details


Form 4	79.47%	10.38M	$1.64	$17.03M	Oct 17, 2022	29.25M	Purchase	—	Oct 13
Form 4	72.21%	6.32M	$1.91	$12.07M	Mar 18, 2022	18.87M	Purchase	—	Mar 16
Form 4	76.74%	3.80M	$4.75	$18.05M	May 20, 2020	12.55M	Purchase	—	May 18
Form 4	-17.91%	-4.16M	$20.00	—	May 15, 2019	21.78M	Buy-Options	—	May 13
Form 3	—	—	—	—	May 08, 2019	2.71M	—	—	—

Showing 5 results

Evelo Biosciences, Inc.

Investor

Updated Jun 01, 2022

View Quote Details


Form 4	288.55%	27.40M	$1.46	$40.00M	Jun 01, 2022	50.43M	Purchase	—	May 27
Form 4	1.39%	130.00K	$15.00	$1.95M	Feb 04, 2021	23.03M	Purchase	—	Feb 02
Form 4	99.33%	4.67M	$3.75	$17.50M	Jul 01, 2020	22.90M	Purchase	—	Jun 29
Form 4	-71.05%	-44.74M	$16.00	$4.50M	May 15, 2018	18.23M	Buy-Options	—	May 11
Form 3	—	—	—	—	May 08, 2018	3.33M	—	—	—

Showing 5 results

Rubius Therapeutics, Inc.

Investor

Updated Mar 23, 2021

View Quote Details


Form 4	0.89%	210.00K	$29.00	$6.09M	Mar 23, 2021	38.51M	Purchase	—	Mar 19

Showing 1 results